Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.
Also called NCT04133168
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 458 participants
- Sponsor
- Registry
-
NCT04133168
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, France, Germany, Hong Kong SAR China, Italy, Netherlands, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04133168. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-24 (actual); primary completion 2022-11-10 (actual). Results posted on 2023-12-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
- Acronym
- FROZEN-AF
- Condition
- Paroxysmal Atrial Fibrillation
- Intervention (Device)
- Boston Scientific Cardiac Cryoablation System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct04133168- Content hash
b91ebc9290b8343d2e1ca01a543410a156a6831564f058db4740b6436bdd05b8